Skip to Main Content

File this under ‘How curious.’

After  generic versions of a key hepatitis B treatment debuted in 2014, they helped patients save money over the next few years. Yet at the same time, the average out-of-pocket spending on those generics actually rose, even though nearly a dozen copycat versions were available, suggesting competition failed to work sufficiently.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment